Search results for "PEPTIDE"

showing 10 items of 4589 documents

Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome.

2006

Abstract Context: An altered lipid profile is common in polycystic ovary syndrome (PCOS) and is usually characterized by increased triglycerides and low high-density lipoprotein (HDL)-cholesterol levels. In the general population, these alterations are often associated with the increase of small low-density lipoproteins (LDLs) in the so-called “atherogenic lipoprotein phenotype” (ALP) that determines a further increase of cardiovascular risk. In this study, we evaluated the presence of ALP in the plasma of women with PCOS. Setting: Measurements and analysis of LDL size were performed at the Clinic of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital, Zurich. PCOS patients…

Adultmedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical BiochemistryPopulationClinical nutritionBiologyBiochemistryAnovulationEndocrinologyDiabetes mellitusInternal medicinemedicineHumansInsulinParticle SizeeducationTriglyceridesAtherogenic lipoprotein low-density lipoproteins polycystic ovary syndromeeducation.field_of_studymedicine.diagnostic_testBiochemistry (medical)HyperandrogenismCholesterol HDLnutritional and metabolic diseasesmedicine.diseasePolycystic ovaryLipoproteins LDLEndocrinologyPhenotypelipids (amino acids peptides and proteins)FemaleLipid profileLipoproteinPolycystic Ovary SyndromeThe Journal of clinical endocrinology and metabolism
researchProduct

Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy.

2013

Abstract Objective To determine the spectrum of gene mutations and the genotype–phenotype correlations in patients with Autosomal Dominant Hypercholesterolemia (ADH) identified in Italy. Methods The resequencing of LDLR , PCSK9 genes and a selected region of APOB gene were conducted in 1018 index subjects clinically heterozygous ADH and in 52 patients clinically homozygous ADH. The analysis was also extended to 1008 family members of mutation positive subjects. Results Mutations were detected in 832 individuals: 97.4% with LDLR mutations, 2.2% with APOB mutations and 0.36% with PCSK9 mutations. Among the patients with homozygous ADH, 51 were carriers of LDLR mutations and one was an LDLR / …

Adultmedicine.medical_specialtyHeterozygoteSettore MED/09 - Medicina InternaApolipoprotein BCoronary DiseaseBiologyGene mutationmedicine.disease_causeHyperlipoproteinemia Type IITendonschemistry.chemical_compoundReference ValuesInternal medicinemedicineXanthomatosisHumansGeneAllelesGenetic Association StudiesAgedGeneticsMutationCholesterolPCSK9Cholesterol HDLSerine EndopeptidasesSmokingAlcohol Dehydrogenasenutritional and metabolic diseasesCholesterol LDLMiddle AgedEndocrinologyPhenotypechemistryItalyLDL receptorMutationbiology.proteinAutosomal dominanthypercholesterolemia LDL receptor Apolipoprotein B PCSK9 Mutationslipids (amino acids peptides and proteins)Allelic heterogeneityFemaleProprotein ConvertasesProprotein Convertase 9Cardiology and Cardiovascular MedicineAtherosclerosis
researchProduct

The Cohort of Long-term Survivors at the German Childhood Cancer Registry

2008

Background With the increasing number of long-term survivors among patients diagnosed with cancer during childhood, questions concerning late effects have become a major research topic. To ascertain late effects, it is necessary to contact former patients. An essential requirement for such studies is a long-term surveillance (LTS) of former childhood cancer patients in their adolescence and their adulthood. The paper describes the role of the German Childhood Cancer Registry (GCCR) in LTS. A cohort of long-term survivors has been built up over the years. The characteristics of this LTS cohort and strategies for further improvement of LTS will be presented. Patients and methods Since 1980 th…

Adultmedicine.medical_specialtyPediatricsAdolescentLymphomaPopulationCohort StudiesYoung AdultQuality of lifeNeoplasmsEpidemiologymedicineHumansRegistriesSurvivorsYoung adultChildeducationChildhood Cancer Registryeducation.field_of_studyLeukemiaBrain Neoplasmsbusiness.industryNeoplasms Second PrimaryCancer registryChild PreschoolPediatrics Perinatology and Child HealthCohortlipids (amino acids peptides and proteins)businessFollow-Up StudiesCohort studyKlinische Pädiatrie
researchProduct

Cardiac manifestations of Anderson-Fabry disease in heterozygous females.

2002

AbstractObjectivesWe sought to define the prevalence of cardiac involvement in female patients with Anderson–Fabry disease (AFD).BackgroundAnderson–Fabry disease is a rare inborn X-linked lysosomal storage disorder. Globotriaosylceramide (Gb3), the major substrate of the deficient α-galactosidase A enzyme, accumulates progressively in vulnerable cells, including the cardiovascular system. It has been believed that heterozygous females have less cardiac involvement than hemizygous males with AFD.MethodsWe performed two-dimensional echocardiographic examinations of female patients heterozygous for AFD.ResultsSince 1997, a total of 55 female patients (mean age, 39.6 years; range, 6.1 to 70.8 y…

Adultmedicine.medical_specialtyPediatricsHeterozygoteendocrine system diseasesHeart diseaseAdolescentSystoleHeart Valve DiseasesDiseaseVentricular Dysfunction LeftFemale patientotorhinolaryngologic diseasesmedicinePrevalenceHumanscardiovascular diseasesProspective StudiesSystoleProspective cohort studyChildneoplasmsAgedVascular diseasebusiness.industryAge FactorsMiddle Agedmedicine.diseaseFabry diseasehumanitiesSurgeryPedigreeAnderson-Fabry DiseaseEchocardiographyFabry Diseaselipids (amino acids peptides and proteins)FemaleHypertrophy Left VentricularCardiology and Cardiovascular MedicinebusinessJournal of the American College of Cardiology
researchProduct

Vitrification of preimplantation genetically diagnosed human blastocysts and its contribution to the cumulative ongoing pregnancy rate per cycle by u…

2008

Objective To evaluate the survival rate and clinical results of our vitrification procedure on preimplantation genetic diagnosis (PGD) blastocysts and to calculate its actual contribution to the reproductive outcome per cycle. Design Retrospective clinical study. Setting University Institute IVI, Valencia, Spain. Patient(s) Patients who requested cryotransfer of surplus PGD blastocysts after failed fresh elective transfer. Intervention(s) Retrospectively collected data during 2 years of experience with blastocyst vitrification. Main Outcome Measure(s) Primary outcome measures were the following: blastocyst recovery and survival; cryotransfer cancellation; and the implantation, pregnancy (PR…

Adultmedicine.medical_specialtyPregnancy RateFertilization in VitroBiologyPreimplantation genetic diagnosisCryopreservationAndrologyEmbryo Culture TechniquesPregnancymedicineHumansVitrificationBlastocystGenetic TestingSurvival ratePreimplantation DiagnosisRetrospective StudiesGynecologyCryopreservationPregnancyObstetrics and Gynecologyrespiratory systemmedicine.diseaseEmbryo TransferEmbryo transferCoculture TechniquesPregnancy ratemedicine.anatomical_structureBlastocystTreatment OutcomeReproductive MedicineInfertilityembryonic structureslipids (amino acids peptides and proteins)FemaleFertility and sterility
researchProduct

How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?

2007

Despite their young age, women with polycystic ovary syndrome (PCOS) have increased cardiovascular risk. Besides normal concentrations of low-density lipoprotein (LDL) cholesterol, dyslipidemia is very common and includes elevated triglyceride levels and low high-density lipoprotein cholesterol concentrations. Recent findings also showed that women with PCOS have qualitative LDL alterations, with increased levels of atherogenic small, dense LDL particles. Such lipid abnormalities constitute a common form of dyslipidemia, the so-called atherogenic lipoprotein phenotype (ALP), associated with a greater cardiovascular risk. Weight reduction and increased physical activity may constitute first-…

Adultmedicine.medical_specialtySettore MED/09 - Medicina Interna10265 Clinic for Endocrinology and Diabetology610 Medicine & healthRisk AssessmentSeverity of Illness IndexSettore MED/13 - Endocrinologiachemistry.chemical_compoundWeight lossInternal medicinemedicineHumansatherosclerosis high-density lipoprotein cholesterol polycystic ovary syndrome small and dense low-density lipoprotein triglyceridesDyslipidemiasTriglyceridebusiness.industryCholesterolCholesterol HDLnutritional and metabolic diseasesObstetrics and Gynecology2729 Obstetrics and GynecologyCholesterol LDLmedicine.diseaseAtherosclerosisPrognosisPolycystic ovaryMetforminEndocrinologyTreatment OutcomechemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Drug Therapy CombinationFemaleControlled Clinical Trials as Topicmedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPioglitazoneDyslipidemiamedicine.drugLipoproteinPolycystic Ovary Syndrome
researchProduct

Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.

2009

OBJECTIVE: Dyslipidaemia is very common in patients with polycystic ovary syndrome (PCOS) but, beyond plasma lipids, atherogenic lipoprotein (Lp) and apolipoprotein (apo) alterations are still ill defined. DESIGN: We measured concentrations of apoB, Lp(a) and small, dense low-density lipoprotein (LDL) in 42 patients with PCOS [age: 28 +/- 7 years, body mass index (BMI): 27 +/- 5 kg/m(2)] vs. 37 age- and BMI-matched healthy controls. METHODS: Elevated Lp(a) levels considered were those > 30 mg/dl while elevated apoB concentrations were those > 100 g/l. RESULTS: Polycystic ovary syndrome showed increased triglycerides levels (p = 0.0011) and lower high-density lipoprotein (HDL)-cholesterol co…

Adultmedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein B10265 Clinic for Endocrinology and Diabetology610 Medicine & health2700 General MedicineSettore MED/13 - EndocrinologiaBody Mass Indexchemistry.chemical_compoundYoung AdultRisk FactorsInternal medicinemedicinedyslipidemia lipoproteins polycystic ovary syndromeHumansProspective cohort studyApolipoproteins BDyslipidemiasbiologyCholesterolbusiness.industryVascular diseaseCase-control studynutritional and metabolic diseasesGeneral MedicineCholesterol LDLmedicine.diseasePolycystic ovaryEndocrinologychemistry10036 Medical ClinicCardiovascular DiseasesCase-Control Studiesbiology.proteinlipids (amino acids peptides and proteins)FemalebusinessBody mass indexLipoproteinLipoprotein(a)Polycystic Ovary SyndromeInternational journal of clinical practice
researchProduct

LONG-ACTING AND SELECTIVE SUPPRESSION OF GROWTH HORMONE SECRETION BY SOMATOSTATIN ANALOGUE SMS 201-995 IN ACROMEGALY

1984

In 6 of 7 acromegalic patients a single subcutaneous injection of 50 micrograms of a new octapeptide somatostatin analogue (SMS 201-995) reduced serum growth hormone (GH) from 30 +/- 12 ng/ml to 1.4 +/- 0.4 (mean +/- SEM). Serum GH remained below basal concentration for 9 h. In the remaining patient who had very high basal preprandial serum GH, SMS 201-995 produced a reduction in serum GH of only 20%. Plasma glucose concentrations were increased to the upper limits of the normal range when a high-carbohydrate meal was consumed 2 h after injection. In non-diabetic patients plasma glucose did not exceed 129 mg/dl. The 40% decrease in plasma glucagon, which lasted for 7 h after SMS 201-995 inj…

Adultmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPeptide hormoneOctreotideEatingSubcutaneous injectionInternal medicineAcromegalymedicineHumansInsulinAgedChemotherapyMealChemistryGeneral MedicineGlucose Tolerance TestMiddle AgedGlucagonmedicine.diseaseGrowth hormone secretionEndocrinologySomatostatinBasal (medicine)Growth HormoneAcromegalySomatostatinThe Lancet
researchProduct

Growth factor concentrations and their placental mRNA expression are modulated in gestational diabetes mellitus: possible interactions with macrosomia

2009

Abstract Background Gestational diabetes mellitus (GDM) is a form of diabetes that occurs during pregnancy. GDM is a well known risk factor for foetal overgrowth, termed macrosomia which is influenced by maternal hypergycemia and endocrine status through placental circulation. The study was undertaken to investigate the implication of growth factors and their receptors in GDM and macrosomia, and to discuss the role of the materno-foeto-placental axis in the in-utero regulation of foetal growth. Methods 30 women with GDM and their 30 macrosomic babies (4.75 ± 0.15 kg), and 30 healthy age-matched pregnant women and their 30 newborns (3.50 ± 0.10 kg) were recruited in the present study. Serum …

Adultmedicine.medical_specialtyTunisiaendocrine system diseasesOffspringPlacentalcsh:Gynecology and obstetricsFetal MacrosomiaReceptor Platelet-Derived Growth Factor betaGrowth factor receptorEpidermal growth factorPregnancyPlacentaDiabetes mellitusInternal medicineResearch articleObstetrics and GynaecologyFetal macrosomiamedicineHumansRNA MessengerInsulin-Like Growth Factor Ilcsh:RG1-991PregnancyEpidermal Growth Factorbusiness.industryInfant NewbornObstetrics and Gynecologynutritional and metabolic diseasesmedicine.diseasefemale genital diseases and pregnancy complicationsUp-RegulationGestational diabetesDiabetes Gestationalmedicine.anatomical_structureEndocrinologyInsulin-Like Growth Factor Binding Protein 3Case-Control StudiesGrowth HormoneIntercellular Signaling Peptides and ProteinsFemaleFibroblast Growth Factor 2businessBMC Pregnancy and Childbirth
researchProduct

Cizolirtine Citrate, an Effective Treatment for Symptomatic Patients with Urinary Incontinence Secondary to Overactive Bladder: A Pilot Dose-Finding …

2009

Abstract Background A dose-finding study was performed as the first step in the clinical development of the new drug, cizolirtine citrate. Objective To assess the efficacy and safety of cizolirtine citrate in overactive bladder with urinary incontinence. Design, setting, and participants Seventy-nine outpatients with clinical overactive bladder and/or urodynamic diagnosis of detrusor overactivity were randomized in a multicentre, 12-wk, double-blind, pilot trial. Interventions Patients received cizolirtine citrate 400mg bid (C400), cizolirtine citrate 200mg bid (C200), or placebo. Measurements Patients recorded efficacy variables in 7- and 14-d bladder diaries: urinary incontinence episodes…

Adultmedicine.medical_specialtyVomitingCalcitonin Gene-Related PeptideUrologyUrinary systemVision DisordersUrologyPilot ProjectsUrinary incontinenceSubstance PPlaceboDizzinesslaw.inventionYoung AdultDouble-Blind MethodRandomized controlled triallawmedicineHumansAdverse effectAgedAged 80 and overUrinary bladderDose-Response Relationship DrugUrinary Bladder Overactivebusiness.industryNauseaMiddle Agedmedicine.diseaseUrodynamicsUrinary Incontinencemedicine.anatomical_structureTolerabilityOveractive bladderPyrazolesFemalemedicine.symptombusinessEuropean Urology
researchProduct